Table 2 Expected and observed frequencies, related risk of occurrence of malignancies of different site of origin in psoriasis families

Breast

Females

20

21

1.0, p= 0,8736

Lungs

Males

26

26

1.0, p=1.0

Females

13

9

1,2, p=0,3891

Colorectal

Males

15

16

1.0, p=0,8553

Females

9

11

0.9, p=0,6518

Stomach

Males

5

6

0.9, p=0,7618

Females

4

10

0.6, p=0,1066

Liver

Males

1

1

1.0, p=1.0

Females

2

1

1.3,p=0,5632

Melanoma

Males

2

2

1.0, p=1.0

Females

5

2

1.4, p=0,2554

Kidney

Males

4

5

0.9, p=0,7378

Females

6

4

1.2, p=0,5253

Prostate

Males

15

16

1.0, p=0,8553

Larynx

Males

6

3

1.3, p=0,3152

Females

1

0,5

1.3, p=0,1964

CNS

Males

3

2

1.2, p=0,6539

Females

4

2

1.4, p=0,4130

Leukaemia

Males

5

2

1.4, p=0,2552

Females

5

2

1.4, p=0,2554

Hodgkin Lymphoma

Males

2

0,2

1.8, p=0.002*

Females

0

0

-

Bones

Males

1

1

1.0, p=1.0

Females

2

1

1.3, p=0,5632

Bladder

Males

1

1

1.0, p=1.0

Females

0

2

P=0,1569

NHL

Males

1

1

1.0, p=1.0

Females

1

1

1.0, p=1.0

Pancreas

Males

2

3

0.8, p=0,6539

Females

3

3

1.0, p=1.0

Uterus

Females

3

7

0.6, p=0,2039

Ovary

Females

4

5

0.9, p=0,7379

Thyroid

Males

0

0.5

P=0.0523

Females

2

2

1.0, p=1.0

Cervix

Females

5

4

1.1, p=0,7379

Non-melanoma skin cancer

Males

9

9

1.0, p=1.0

Females

9

8

1.0, p=0,8069